EPS for Pershing Gold (PGLC) Expected At $-0.10; Abaxis, Inc. (ABAX) Covered By 1 Bullish Analysts Last Week

July 18, 2018 - By Eric Painter

Abaxis, Inc. (NASDAQ:ABAX) Logo

Analysts expect Pershing Gold Corporation (NASDAQ:PGLC) to report $-0.10 EPS on August, 10.They anticipate $0.02 EPS change or 16.67% from last quarter’s $-0.12 EPS. After having $-0.12 EPS previously, Pershing Gold Corporation’s analysts see -16.67% EPS growth. The stock decreased 0.59% or $0.01 during the last trading session, reaching $1.68. About 24,307 shares traded. Pershing Gold Corporation (NASDAQ:PGLC) has declined 32.62% since July 18, 2017 and is downtrending. It has underperformed by 45.19% the S&P500. Some Historical PGLC News: 16/04/2018 – BNY Mellon’s Pershing Launches New Retirement Plan Oversight Tool; 10/04/2018 – Elite Advisory Firms Not Feeling the Pressure to Reduce Fees: New Poll by BNY Mellon’s Pershing Advisor Solutions; 09/05/2018 – BNY Mellon’s Pershing Adds Capital First Trust Company to Its Trust Network; 05/04/2018 – Investors Withdrew Two-Thirds of Eligible Cash From Pershing in 2017 (Video); 26/04/2018 – Pershing Gold Appoints Jeffrey G. Clevenger to Board of Directors; 26/04/2018 – Pershing Gold Appoints Jeffrey G. Clevenger to Board; 15/05/2018 – PERSHING CONFIRMS UNITED TECHNOLOGIES STAKE IN 1Q 13F; 13/03/2018 – PERSHING CITES PORTFOLIO MANAGEMENT PURPOSES FOR ADP SALES; 15/05/2018 – ACKMAN SAYS MOVING OUT OF INVESTOR RELATIONS ROLE AT PERSHING; 14/05/2018 – PERSHING GOLD CORP QTRLY NET LOSS PER COMMON SHARE $0.12

Among 7 analysts covering Abaxis (NASDAQ:ABAX), 1 have Buy rating, 1 Sell and 5 Hold. Therefore 14% are positive. Abaxis had 8 analyst reports since January 25, 2018 according to SRatingsIntel. Stifel Nicolaus maintained the shares of ABAX in report on Thursday, January 25 with “Hold” rating. Stephens maintained the shares of ABAX in report on Friday, January 26 with “Hold” rating. The stock of Abaxis, Inc. (NASDAQ:ABAX) has “Buy” rating given on Monday, January 29 by Northcoast. The rating was maintained by Stifel Nicolaus on Friday, April 27 with “Hold”. Canaccord Genuity maintained the stock with “Hold” rating in Monday, January 29 report. The rating was downgraded by Sidoti on Wednesday, May 16 to “Neutral”. Bank of America maintained Abaxis, Inc. (NASDAQ:ABAX) rating on Thursday, February 8. Bank of America has “Underperform” rating and $48 target. Credit Suisse upgraded the stock to “Hold” rating in Wednesday, May 16 report. See Abaxis, Inc. (NASDAQ:ABAX) latest ratings:

16/05/2018 Broker: Credit Suisse Rating: Hold Upgrade
16/05/2018 Broker: Sidoti Old Rating: Buy New Rating: Neutral Downgrade
27/04/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $57 New Target: $62 Maintain
08/02/2018 Broker: Bank of America Old Rating: Underperform New Rating: Underperform Old Target: $46 New Target: $48 Maintain
29/01/2018 Broker: Northcoast Rating: Buy New Target: $90.0 Maintain
29/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $65.0 Maintain
26/01/2018 Broker: Stephens Rating: Hold New Target: $60.0 Maintain
25/01/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $57.0 Maintain

Another recent and important Abaxis, Inc. (NASDAQ:ABAX) news was published by Streetinsider.com which published an article titled: “Zoetis (ZTS), Abaxis (ABAX) Announce HSR Clearance for Zoetis’ Acquisition of Abaxis” on July 06, 2018.

The stock decreased 0.06% or $0.05 during the last trading session, reaching $83.3. About 47,367 shares traded. Abaxis, Inc. (NASDAQ:ABAX) has risen 69.53% since July 18, 2017 and is uptrending. It has outperformed by 56.96% the S&P500. Some Historical ABAX News: 16/05/2018 – ZOETIS – EXPECTS DEAL TO HAVE IMPACT ON 2018 EARNINGS RELATED TO CUSTOMARY CLOSING ACTIVITIES; ON ADJUSTED BASIS, CO DOES NOT EXPECT MATERIAL IMPACT; 16/05/2018 – ZOETIS TO BUY ABAXIS BUY PRICE OF US $83/SHR IN CASH; 16/05/2018 – Zoetis To Buy Veterinary Diagnostics Company Abaxis For A 16% Premium — MarketWatch; 14/05/2018 – Abaxis Closes Above 50-Day Moving Average: Technicals; 16/05/2018 – ZOETIS INC – PURCHASE PRICE OF US $83 PER SHARE IN CASH, OR APPROXIMATELY $2.0 BLN IN AGGREGATE; 11/05/2018 – Abaxis Presenting at UBS Conference May 22; 16/05/2018 – Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Abaxis, Inc. (ABAX) on Behalf of Stockholders and; 21/04/2018 DJ Abaxis Inc, Inst Holders, 1Q 2018 (ABAX); 16/05/2018 – MOODY’S SAYS ZOETIS’ PURCHASE OF ABAXIS IS CREDIT NEGATIVE; 16/05/2018 – Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Abaxis, Inc. (ABAX) on Behalf of Stockholders and Encourages Investors to Contact the Firm

Since January 30, 2018, it had 0 buys, and 13 insider sales for $5.31 million activity. $98,266 worth of Abaxis, Inc. (NASDAQ:ABAX) shares were sold by ARON KENNETH. EVENHUIS HENK also sold $333,460 worth of Abaxis, Inc. (NASDAQ:ABAX) shares. Shares for $664,030 were sold by Henkel Achim on Tuesday, May 29. 1,650 shares were sold by TOCKMAN CRAIG, worth $122,652 on Wednesday, January 31. 2,000 Abaxis, Inc. (NASDAQ:ABAX) shares with value of $149,255 were sold by SINGH PRITHIPAL. Another trade for 10,000 shares valued at $689,851 was made by WOOD DONALD PETER on Tuesday, March 6. CASEY MICHAEL D had sold 5,000 shares worth $355,327 on Thursday, March 8.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. The company has market cap of $1.91 billion. It operates in two divisions, Medical Market and Veterinary Market. It has a 71.2 P/E ratio. The firm offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.

Investors sentiment increased to 1.48 in Q1 2018. Its up 0.21, from 1.27 in 2017Q4. It improved, as 11 investors sold Abaxis, Inc. shares while 45 reduced holdings. 37 funds opened positions while 46 raised stakes. 20.94 million shares or 3.32% less from 21.66 million shares in 2017Q4 were reported. Rhumbline Advisers holds 0.01% or 64,935 shares in its portfolio. State Of Tennessee Treasury Department holds 16,045 shares or 0.01% of its portfolio. Barclays Pcl invested in 8,599 shares. Eaton Vance Mgmt holds 0.01% of its portfolio in Abaxis, Inc. (NASDAQ:ABAX) for 60,299 shares. Ubs Asset Management Americas Incorporated accumulated 11,248 shares or 0% of the stock. Tower Rech Capital (Trc) holds 0.01% or 2,161 shares. Moreover, Wesbanco State Bank has 0.02% invested in Abaxis, Inc. (NASDAQ:ABAX) for 5,500 shares. Ls Inv Advsrs Limited Liability Corp owns 757 shares for 0% of their portfolio. Amalgamated Bankshares, a New York-based fund reported 3,166 shares. Hl Financial Lc, Kentucky-based fund reported 4,725 shares. Geode Cap Management Lc, Massachusetts-based fund reported 213,651 shares. D E Shaw And Co stated it has 3,282 shares. Brown Mgmt Limited Liability has invested 1.74% of its portfolio in Abaxis, Inc. (NASDAQ:ABAX). Paloma Mngmt reported 13,167 shares. Stratos Wealth Ltd, Ohio-based fund reported 110 shares.

Pershing Gold Corporation engages in the exploration, development, and mining of gold and precious metals primarily in Nevada. The company has market cap of $56.50 million. It focuses on the exploration of Relief Canyon properties covering an area of approximately 25,000 acres in Pershing County in northwestern Nevada. It currently has negative earnings. The Relief Canyon properties comprise approximately 948 owned unpatented mining claims, 120 owned millsite claims, 172 leased unpatented mining claims, and 2,235 acres of leased and 2,770 acres of subleased private lands.

Abaxis, Inc. (NASDAQ:ABAX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.